Renaissance Technologies LLC Has $5.35 Million Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Renaissance Technologies LLC decreased its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 1.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,755,513 shares of the biopharmaceutical company’s stock after selling 16,900 shares during the quarter. Renaissance Technologies LLC owned 3.58% of Puma Biotechnology worth $5,354,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Gateway Wealth Partners LLC acquired a new stake in Puma Biotechnology during the 4th quarter worth about $31,000. C2C Wealth Management LLC purchased a new position in Puma Biotechnology during the fourth quarter valued at approximately $37,000. Franklin Resources Inc. purchased a new position in Puma Biotechnology during the third quarter valued at approximately $41,000. Virtu Financial LLC purchased a new stake in Puma Biotechnology in the 3rd quarter worth approximately $68,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Puma Biotechnology by 36.5% during the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 6,126 shares during the period. 61.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, February 28th. StockNews.com raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 16th.

Puma Biotechnology Stock Performance

PBYI stock opened at $2.86 on Monday. The firm has a 50 day moving average of $3.10 and a two-hundred day moving average of $3.02. Puma Biotechnology, Inc. has a 12 month low of $2.23 and a 12 month high of $5.34. The company has a market capitalization of $141.89 million, a price-to-earnings ratio of 5.96 and a beta of 1.34. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The firm had revenue of $59.10 million for the quarter, compared to the consensus estimate of $52.50 million. As a group, equities analysts anticipate that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.